Jamie L. Koprivnikar, MD

Drs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.

Clinicians review the MEDALIST trial, which evaluated luspatercept in the second-line setting and comment on updated data from MEDALIST that was recently presented at the annual ASH 2023 meeting.

Dr Hana Safah discusses the role of stem cell transplant and reviews the eligibility criteria.

Experts comment on factors that influence their decision-making when treating patients with lower-risk MDS.

Insights into treatment goals and review of the current treatment landscape for lower-risk MDS.

Clinicians discuss the importance of early detection in patients with MDS as well as providing insights into some of the unmet needs in MDS, such as a better understanding of the role of molecular alterations and its specific impact in MDS.

Hana Safah, MD explains how the risk stratification for MDS has evolved over time and provides an in-depth of the current risk stratification tools, IPSS, IPSS-R and IPSS-M.

Drs Safah and Koprivnikar review updates made to the WHO and ICC guidelines when classifying MDS as well as discussing the impact of molecular alterations when treating MDS.

Experts review best practices for identifying and diagnosing patients with lower-risk MDS.

Jamie L. Koprivnikar, MD, closes by sharing some future insights and remaining unmet needs for patients with myelodysplastic syndrome.

Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.

A review of the rationale and study design of the phase 3 COMMANDS trial and subsequent subgroup analysis data recently presented at the ASCO and EHA 2023 Annual Meetings.

Jamie L. Koprivnikar, MD, reviews luspatercept as a treatment option in myelodysplastic syndrome and the adverse events most frequently seen with her patients in clinical practice.

Dr Jamie L. Koprivnikar comments on the currently unmet needs for patients with low-risk myelodysplastic syndrome in the front-line setting.

Jamie L. Koprivnikar, MD, details how her treatment approaches differ for patients with low-risk versus high-risk myelodysplastic syndrome.

Dr Jamie L. Koprivnikar describes her general approaches to diagnosing and risk stratifying patients with myelodysplastic syndrome, and how she differentiates high-risk and low-risk disease.

Jamie L. Koprivnikar, MD, presents the case of a 72-year-old woman diagnosed with single lineage dysplasia myelodysplastic syndrome and shares her initial impressions.